Professional

Professional Biography: Kristin Peck

Kristin Peck is the Chief Executive Officer of Zoetis Inc., the world’s leading animal health company, a position she has held since January 2020. Under her leadership, Zoetis has undergone a strategic transformation that has positioned the company at the forefront of veterinary biotechnology, digital diagnostics, and global market innovation. Ms. Peck’s tenure has been characterized by disciplined capital allocation, breakthrough therapeutic development in monoclonal antibodies, and the integration of artificial intelligence into veterinary practice—fundamentally reshaping how animal health care is delivered worldwide.

Leadership and Strategic Vision

As CEO, Ms. Peck has championed what the company terms its “Continuum of Care” strategy, an integrated approach that encompasses prediction, prevention, detection, and treatment across the animal health spectrum. Her leadership philosophy combines rigorous financial discipline with bold innovation, a duality that has enabled Zoetis to defend core revenue streams while pursuing transformative opportunities in emerging therapeutic categories. She has navigated the company through significant challenges, including the global COVID-19 pandemic and evolving market dynamics, while maintaining Zoetis’s position as the industry leader with a market capitalization exceeding $80 billion.

A defining achievement of her tenure has been the commercialization of the company’s “pain franchise,” anchored by Librela (bedinvetmab) and Solensia (frunevetmab)—revolutionary monoclonal antibody therapies for osteoarthritis pain in dogs and cats. These biologics represent a watershed moment in veterinary pharmacology, offering pet owners alternatives to traditional NSAIDs with novel mechanisms of action. Ms. Peck has also overseen substantial expansion of Zoetis’s digital capabilities, including the development of the Vetscan Imagyst platform, an AI-powered diagnostic system that brings advanced imaging analysis to veterinary clinics, and the acquisition of Basepaws, a genomic data company that enhances the company’s precision medicine capabilities.

Professional Background and Pfizer Legacy

Ms. Peck’s journey to the helm of Zoetis is distinguished by a unique combination of strategic consulting expertise and deep operational experience in the pharmaceutical industry. Prior to becoming CEO, she served in progressively senior roles at Zoetis, including Executive Vice President and Group President, where she led the U.S. operations and was instrumental in shaping the company’s international expansion strategy.

Her connection to Zoetis predates its existence as an independent company. At Pfizer Inc., Ms. Peck served as Executive Vice President of Worldwide Business Development and Innovation, holding a seat on Pfizer’s Executive Leadership Team. In this capacity, she was the architect of the strategic analysis that led to the decision to spin off Pfizer’s Animal Health and Nutrition businesses. Her work on this complex corporate restructuring—which required untangling shared supply chains, intellectual property, and IT systems—was pivotal in creating Zoetis as an independent, publicly traded entity through its initial public offering in 2013. This experience provided her with an intimate understanding of the company’s foundational structure and positioned her uniquely to lead it as an autonomous enterprise.

Early Career and Educational Foundation

Ms. Peck’s leadership philosophy is underpinned by rigorous training in finance and strategic management. She began her career at The Boston Consulting Group (BCG), where she developed frameworks for operational efficiency and market entry strategies while working on complex problems for global clients. This consulting crucible taught her to synthesize vast amounts of data into actionable strategies—a skill clearly evident in her current executive decision-making.

Following BCG, Ms. Peck held roles in private equity and real estate finance at prestigious firms including The Prudential Realty Group, The O’Connor Group, and J.P. Morgan. This financial sector experience provided her with deep expertise in asset valuation, capital markets, and shareholder value creation—competencies that have proven instrumental in her management of Zoetis’s balance sheet, particularly regarding strategic share repurchases and the divestiture of lower-margin assets such as the Medicated Feed Additive (MFA) portfolio.

Education and Credentials

Ms. Peck holds a Bachelor’s degree from Georgetown University, where she developed a worldview centered on international relations and policy—a perspective that continues to inform her approach to global market development. She earned her Master of Business Administration (MBA) from Columbia Business School, one of the world’s premier institutions for finance and strategic management, where she honed the skills in corporate finance and organizational strategy that define her executive leadership today.

Global Impact and Innovation

Beyond financial performance, Ms. Peck has positioned Zoetis as a leader in corporate social responsibility through initiatives such as the African Livestock Productivity and Health Advancement (A.L.P.H.A.) program. This initiative, which secured $15.3 million in grant funding, demonstrates her commitment to creating shared value by improving livestock health and livelihoods in Sub-Saharan Africa while simultaneously developing long-term markets for Zoetis products.

Under her direction, Zoetis has also pioneered “One Health” initiatives that bridge veterinary and human medicine, including partnerships with institutions like the Mayo Clinic to advance diagnostic capabilities that benefit both animal and human patients. Her strategic vision recognizes that innovations in veterinary medicine can serve as proving grounds for technologies that later translate to human healthcare applications, a concept that is revolutionizing cross-species therapeutic development.

Industry Recognition

Ms. Peck’s leadership has been recognized throughout the animal health and broader business communities. She has successfully steered Zoetis through a period of unprecedented industry transformation, characterized by the humanization of pets, increased investment in animal healthcare, and the integration of biotechnology into veterinary practice. Her ability to balance operational excellence with breakthrough innovation has established a new benchmark for leadership in the life sciences sector.

Current Activities and Future Outlook

As CEO, Ms. Peck continues to drive Zoetis’s expansion into high-growth therapeutic areas while maintaining the company’s core strength in vaccines and parasiticides. She remains focused on leveraging the company’s scale and scientific capabilities to address emerging challenges in animal health, from antimicrobial resistance to climate-related disease vectors. Her strategic partnerships with technology leaders, including recent collaborations with Infosys to enhance digital capabilities, position Zoetis to capitalize on the convergence of biotechnology, data analytics, and connected care delivery systems.

Through her leadership, Kristin Peck has not only sustained Zoetis’s position as the global leader in animal health but has fundamentally redefined what is possible in veterinary medicine, establishing a legacy of innovation that will shape the industry for decades to come.

Sources and References

This biography was compiled from comprehensive research including:

  1. Zoetis Inc. Official Communications
  2. Financial Performance Reports
  3. Innovation and Product Development
  4. Global Health Initiatives
  5. Scientific and Regulatory Information
  6. Strategic Partnerships
  7. Industry Analysis

This biography reflects Ms. Peck’s professional accomplishments and leadership through 2025, compiled from official company communications, financial reports, and industry publications.

Leave a Reply

Your email address will not be published. Required fields are marked *